---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007959"
form_type: "8-K"
ticker: null
cik: "0001733294"
company_name: "Generation Bio Co."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:30:44.962275+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Generation Bio Q1 net loss $74.5M on lease termination; cash runway into 2H 2027

## Summary
- Q1 net loss $74.5M ($1.12/share) includes $56.9M non-cash lease termination charge; vs $32.1M ($0.53) Q1 2023.
- Cash $233.9M at March 31, 2024; expected to fund operations into 2H 2027.
- Presented in vivo T cell delivery data for ctLNP at ASGCT; advancing HSC-targeted ctLNP for sickle cell/beta-thalassemia.
- R&D expenses $14.3M, down from $22.0M YoY; G&A $10.4M, down from $12.9M.
- Collaboration with Moderna for T cell ctLNP; iqDNA platform using rapid enzymatic synthesis advanced.

## SEC filing metadata
- accession: 0001558370-24-007959
- form_type: 8-K
- cik: 0001733294
- company_name: Generation Bio Co.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/0001558370-24-007959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/gbio-20240513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007959
- JSON: https://secwatch.observer/filing/0001558370-24-007959.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007959.txt

## Key facts
- Earnings Releases
  Generation Bio Co. reported the quarter ended March 31, 2024 results: net income Net loss was $74.5 million, or $1.12 basic and diluted net loss per share.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss was $74.5 million, or $1.12 basic and diluted net loss per share
  - Result: reported results
  source text: Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/0001558370-24-007959-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.